Brief: Matinas Biopharma Holdings Reports Positive Interim Data From The Phase 2 Enact Trial Of Mat2203

Matinas BioPharma Holdings

21/10/2022 13:46

Oct 21 (Reuters) - Matinas BioPharma Holdings Inc
 MTNB.A :
    * MATINAS BIOPHARMA HOLDINGS - REPORTS POSITIVE INTERIM DATA
FROM
THE PHASE 2 ENACT TRIAL OF MAT2203 FOR TREATMENT OF CRYPTOCOCCAL
MENINGITIS
    * MATINAS BIOPHARMA HOLDINGS INC - COHORT 4 (AN ALL-ORAL
TREATMENT
REGIMEN WITH MAT2203) MET ITS PRESPECIFIED PRIMARY ENDPOINT
    * MATINAS BIOPHARMA - PLANS TO INITIATE A PHASE 3
REGISTRATION
TRIAL OF MAT2203 AS STEP-DOWN THERAPY IN CRYPTOCOCCAL MENINGITIS
IN Q1 OF 2023
    * MATINAS BIOPHARMA HOLDINGS - OVERALL SURVIVAL IN COHORT 4,
A KEY
SECONDARY ENDPOINT OF THE STUDY, IS 95 % AT TWO WEEKS AND
CURRENTLY 90% OVERALL

Source: (shorturl.at/clBWZ)
Further company coverage:  MTNB.A 
 ((Reuters.Briefs@thomsonreuters.com;))